Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
March 31, 2025 11:29 am ET
Delayed at least 20 minutes

Latest news, events & financials

March 31, 2025

WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial

March 27, 2025

Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial

March 26, 2025

European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

View all

April 24, 2025

Earnings

Merck & Co., Inc. Q1 2025 Earnings Call

Add to Calendar

July 29, 2025

Earnings

Merck & Co., Inc. Q2 2025 Earnings Call

Add to Calendar

October 30, 2025

Earnings

Merck & Co., Inc. Q3 2025 Earnings Call

Add to Calendar

View all

4Q24 Merck Earnings Announcement
PDF

4Q24 Merck Other Financial Disclosures
PDF

View all

Merck & Co., Inc. Q1 2025 Earnings Call

Add to Calendar

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

80+

Phase III programs

30+

Under review

10+

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Sustainability

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our Impact Report 2023/2024

Download our Sustainability financing documents:

2021 Sustainability financing framework

Second-party opinion (SPO) on the bond framework

2023 Sustainability bond allocation report

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our Q4 and full-year 2024 financial results

Merck’s (NYSE: MRK) Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. Full-year 2024 worldwide sales were $64.2 billion, an increase of 7% from full-year 2023. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including […]

Next: Our Q4 and full-year 2024 financial results

illustration of people building bar graph

Innovation

Our Q3 2024 financial results

Merck’s (NYSE: MRK) Q3 2024 financial results represent strong progress across the business and our diverse pipeline. Our company announced worldwide sales of $16.7 billion, an increase of 4% from Q3 2023. “Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond,” said Rob Davis, chairman and chief executive officer. […]

Next: Our Q3 2024 financial results